139 related articles for article (PubMed ID: 35970353)
21. Secondary Acquired Nasolacrimal Duct Obstruction as a Specific Complication of Treatment With Radioactive Iodine (Morphological Study).
Fedorov AA; Atkova EL; Yartsev VD
Ophthalmic Plast Reconstr Surg; 2020; 36(3):250-253. PubMed ID: 31743278
[TBL] [Abstract][Full Text] [Related]
22. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.
Sakahara H; Yamashita S; Suzuki K; Imai M; Kosugi T
Ann Nucl Med; 2007 Nov; 21(9):525-7. PubMed ID: 18030585
[TBL] [Abstract][Full Text] [Related]
23. Tear protein analysis in patients with primary acquired nasolacrimal duct obstruction treated with lacrimal passage intubation.
Yaginuma S; Konno K; Shigeyasu C; Yamada M
Jpn J Ophthalmol; 2021 May; 65(3):409-415. PubMed ID: 33411097
[TBL] [Abstract][Full Text] [Related]
24. Lacrimal sac dacryoliths: predictive factors and clinical characteristics.
Yazici B; Hammad AM; Meyer DR
Ophthalmology; 2001 Jul; 108(7):1308-12. PubMed ID: 11425692
[TBL] [Abstract][Full Text] [Related]
25. Dacryoendoscopic Findings of Patients with Lacrimal Drainage Obstruction Associated with Cancer Treatment.
Kim Y; Lew H
Korean J Ophthalmol; 2022 Dec; 36(6):509-517. PubMed ID: 36220641
[TBL] [Abstract][Full Text] [Related]
26. A simple and evolutional approach proven to recanalise the nasolacrimal duct obstruction.
Chen D; Ge J; Wang L; Gao Q; Ma P; Li N; Li DQ; Wang Z
Br J Ophthalmol; 2009 Nov; 93(11):1438-43. PubMed ID: 19416937
[TBL] [Abstract][Full Text] [Related]
27. Bilateral acquired nasolacrimal duct obstruction secondary to amyloidosis in a 15-year-old.
Dermarkarian CR; Bhatt A; Chévez-Barrios P; Allen RC
J AAPOS; 2021 Apr; 25(2):126-128. PubMed ID: 33652101
[TBL] [Abstract][Full Text] [Related]
28. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients.
Morgenstern KE; Vadysirisack DD; Zhang Z; Cahill KV; Foster JA; Burns JA; Kloos RT; Jhiang SM
Ophthalmic Plast Reconstr Surg; 2005 Sep; 21(5):337-44. PubMed ID: 16234694
[TBL] [Abstract][Full Text] [Related]
29. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
30. Primary balloon dacryoplasty for nasolacrimal duct obstruction in adults: a systematic review.
Poignet B; Sultanik P; Beaujeux P; Koch E; Benkhatar H
Orbit; 2021 Dec; 40(6):455-460. PubMed ID: 32912011
[No Abstract] [Full Text] [Related]
31. Associated morbidity of nasolacrimal duct obstruction--a large community based case-control study.
Nemet AY; Vinker S
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):125-30. PubMed ID: 24146269
[TBL] [Abstract][Full Text] [Related]
32. Nasolacrimal duct obstruction secondary to dermatofibrosarcoma protuberans.
Bryar P; Sun R; Ebroon D
Ophthalmology; 2004 Jul; 111(7):1398-400. PubMed ID: 15234144
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients.
Choi EK; Oh JK; Chung YA; Jeong H; Choi H; Jo K
Int J Med Sci; 2024; 21(3):492-495. PubMed ID: 38250604
[No Abstract] [Full Text] [Related]
34. Epiphora after radioactive iodine ablation for thyroid cancer.
Sun GE; Hatipoglu B
Thyroid; 2013 Feb; 23(2):243-5. PubMed ID: 22946448
[TBL] [Abstract][Full Text] [Related]
35. Use of the Masterka for complex nasolacrimal duct obstruction in children.
Khatib L; Nazemzadeh M; Revere K; Katowitz WR; Katowitz JA
J AAPOS; 2017 Oct; 21(5):380-383. PubMed ID: 28917994
[TBL] [Abstract][Full Text] [Related]
36. Anisometropia and amblyopia in nasolacrimal duct obstruction.
Kipp MA; Kipp MA; Struthers W
J AAPOS; 2013 Jun; 17(3):235-8. PubMed ID: 23602456
[TBL] [Abstract][Full Text] [Related]
37. Antimetabolites as an adjunct to dacryocystorhinostomy for nasolacrimal duct obstruction.
Phelps PO; Abariga SA; Cowling BJ; Selva D; Marcet MM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012309. PubMed ID: 32259290
[TBL] [Abstract][Full Text] [Related]
38. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer.
Dingle IF; Mishoe AE; Nguyen SA; Overton LJ; Gillespie MB
Otolaryngol Head Neck Surg; 2013 May; 148(5):746-52. PubMed ID: 23462656
[TBL] [Abstract][Full Text] [Related]
39. Comparison of bony nasolacrimal canal narrowing with or without primary acquired nasolacrimal duct obstruction in a Japanese population.
Takahashi Y; Nakata K; Miyazaki H; Ichinose A; Kakizaki H
Ophthalmic Plast Reconstr Surg; 2014; 30(5):434-8. PubMed ID: 25098445
[TBL] [Abstract][Full Text] [Related]
40. Congenital nasolacrimal duct obstruction: natural history and the timing of optimal intervention.
Paul TO; Shepherd R
J Pediatr Ophthalmol Strabismus; 1994; 31(6):362-7. PubMed ID: 7714699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
